Duloxetine Capsule, Delayed Release
Product Images NDC 85534-0052

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 85534-0052). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hawaii Repack, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Duloxetine Fig1)

This text provides data on the number of patients with relapse over time for two treatments: placebo and duloxetine. The graph displays the time from randomization to relapse in days, ranging from 0 to 250 days, with various values recorded at different intervals.*

FDA Label Image

Figure10 (Duloxetine Fig10)

This is a description of a study or clinical trial involving the use of placebo compared to duloxetine 60/120 mg once daily for pain management. The text also mentions data related to percent improvement in pain from baseline.*

FDA Label Image

Figure2 (Duloxetine Fig2)

This is a chart illustrating the proportion of patients experiencing a relapse over time in a study comparing a placebo treatment to duloxetine. The x-axis represents the time in days from randomization to relapse, while the y-axis shows the proportion of patients with relapse. The graph demonstrates a comparison between the two treatments over a period of 300 days.*

FDA Label Image

Figure3 (Duloxetine Fig3)

FDA Label Image

Figure4 (Duloxetine Fig4)

FDA Label Image

Figure5 (Duloxetine Fig5)

This text provides information on the percentage of patients improved with different treatments for pain management. It compares the improvement in patients taking Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and a placebo. The text indicates that the results are expressed in terms of the percent improvement in pain from baseline.*

FDA Label Image

Figure6 (Duloxetine Fig6)

FDA Label Image

Figure7 (Duloxetine Fig7)

This data shows the percentage of patients improved with Duloxetine 60 mg once daily compared to placebo over a range of pain improvement from baseline. The graph indicates significant improvements in pain for most patients taking Duloxetine compared to those receiving placebo.*

FDA Label Image

Figure8 (Duloxetine Fig8)

This text indicates a treatment plan involving the use of Duloxetine at a dosage of 60 to 120 mg once daily. The text seems to be related to assessing the improvement in pain levels from a baseline measurement.*

FDA Label Image

Figure9 (Duloxetine Fig9)

This is a comparison chart between Placebo and Duloxetine 60 mg, showing percent improvement in pain from baseline. Duloxetine is shown to be a viable option for pain relief compared to the placebo in the study.*

FDA Label Image

Structure (Duloxetine Structure)

FDA Label Image

20 (Label 20mg)

FDA Label Image

30 (Label 30mg)

This text appears to be a list of various Duloxetine DR Capsules, USP 30mg with different quantities and NDC numbers. The capsules come in a blue color and are marked with DLX30. They are prescription medication and should be kept out of reach of children, stored at 23-25°C. The capsules are manufactured by Asta Pharma USA Inc. The different quantities available include 30, 60, 90, and 120 capsules. The NDC numbers provided are 85634-0052-0, 85534-0052-1, 85534-0052-2, and 85534-0052-3.*

FDA Label Image

40 (Label 40mg)

FDA Label Image

60 (Label 60mg)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.